Following the success in the Australian market, we applied our specialized compliance-to-growth framework to Summit Peptides, a Canadian research peptide brand facing severe platform restrictions and regulatory hurdles.
Following the success in the Australian market, we applied our specialized compliance-to-growth framework to Summit Peptides, a Canadian research peptide brand facing severe platform restrictions and regulatory hurdles.
The Problem
Summit Peptides arrived with a digital infrastructure that triggered multiple red flags under Health Canada’s strict guidelines and Meta/Google advertising policies.
The website and blog sections contained direct references to human consumption and therapeutic outcomes, violating research-only standards.
The inclusion of a Peptide Calculator and a Peptide Guide Ebook created significant regulatory risk by implying dosage and application for human subjects.
The presence of a reviews section detailing user results led to immediate flagging for medicinal claims.
Accumulated violations resulted in full account suspensions across both Meta Ads and Google Ads, halting all paid acquisition.
Ad imagery and copy were repeatedly rejected for violating health and medicinal product policies.
Our Approach
Developed a new set of creatives for Canada that passed pre-clearance by avoiding "before and after" tropes or medicinal aesthetics. Created distinct visual assets tailored to meet the unique requirements of both Meta and Google Ads environments.
Executed a synchronized scaling strategy across Meta and Google Ads, specifically designed for the Canadian research audience. Implemented 24/7 monitoring in the initial weeks to catch and pivot based on any policy signals from ad platform algorithms.
Outcomes
When BodyLab came to us, their entire digital operation was stalled. Non-compliant content had triggered a cascade of platform penalties that made running ads — and growing the brand — nearly impossible.
If you’re running a research peptide brand and struggling with ad disapprovals, scaling limitations, or compliance uncertainty — let’s fix it.
